Mangoceuticals Reports Revenue Decline and Significant Net Loss in Q2 2026

Mangoceuticals, Inc. reported a significant decline in revenue for the second quarter of 2026, generating $68,757 compared to $168,109 in the same period of 2025. For the first half of 2026, revenues totaled $136,621, down from $277,415 in the prior year. The company attributed this decrease primarily to a strategic focus on in-house website development and the testing of a new testosterone replacement therapy (TRT) product in select markets before a full launch. Despite the drop in revenue, the cost of revenues also decreased, reflecting reduced third-party service provider usage and product promotions.

The company's operating expenses saw a notable reduction, with general and administrative expenses falling to $256,095 from $1,245,360 year-over-year. This decline was largely due to decreased legal and accounting fees, although there were increases in travel, consulting, and insurance costs. Salaries and benefits also decreased to $427,298 from $628,343, reflecting changes in personnel. Advertising and marketing expenses increased slightly to $301,445, as the company explored new marketing channels. Overall, Mangoceuticals reported a net loss of $1,312,931 for the quarter, a significant improvement from the $5,415,820 loss reported in the same quarter of 2025.

In terms of strategic developments, Mangoceuticals is in the process of conducting Phase II clinical trials for its patented respiratory illness prevention technology and has entered into a Master Distribution Agreement with Propre Energie, Inc. to market plant-based formulations targeting skin conditions. The company is also preparing to launch its Dermytol product line in the fourth quarter of 2026. Additionally, Mangoceuticals is pursuing a business combination with Nuclea Energy Inc., which could significantly alter its operational structure and shareholder composition.

As of June 30, 2026, Mangoceuticals had total assets of $14.17 million and total liabilities of $1.65 million, resulting in a working capital deficit of approximately $1.2 million. The company reported cash and cash equivalents of $228,688, a decrease from $1.49 million at the end of 2025. The company has indicated a need for additional funding to support ongoing operations and future growth, which may involve raising capital through equity or debt financing. The outlook remains cautious, with management acknowledging the potential for significant dilution to existing shareholders if additional funding is pursued.

Looking ahead, Mangoceuticals plans to continue its focus on marketing and expanding its product offerings in the men's wellness sector, particularly through its telemedicine platform. The company aims to enhance its technology and infrastructure while exploring strategic acquisitions to support its growth strategy. However, the need for additional capital raises concerns about the company's ability to sustain operations without further financing, which may not be available on favorable terms.